Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €40.75 EUR
Change Today +0.62 / 1.54%
Volume 2.5K
As of 8:25 AM 10/5/15 All times are local (Market data is delayed by at least 15 minutes).

vetoquinol sa (VETO) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/10/15 - €41.95
52 Week Low
10/16/14 - €32.40
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VETOQUINOL SA (VETO)

Related News

No related news articles were found.

vetoquinol sa (VETO) Related Businessweek News

No Related Businessweek News Found

vetoquinol sa (VETO) Details

Vétoquinol S.A., a veterinary pharmaceutical laboratory, designs, develops, and sells veterinary drugs and non-medicinal products serving both the companion animals and livestock, and bred for human food markets in Europe, the Americas, and the Asia Pacific region. It offers anti-infective, pain inflammation, and cardiology/nephrology products for dogs, cats, cattle, and pigs. The company’s products include Aurizon, Clavaseptin, Flexadin, Ipakitine, Marbocyl, Propalin, Prilium, Rubénal, Tolfine/Tolfédine, and Zentonil. The company was founded in 1933 and is headquartered in Lure, France.

2,004 Employees
Last Reported Date: 04/20/15
Founded in 1933

vetoquinol sa (VETO) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €395.3K
Chief Operating Officer
Total Annual Compensation: €335.3K
Chairman, Member of Strategy Committee, Chair...
Total Annual Compensation: €174.5K
Chief Pharmacist
Total Annual Compensation: €137.1K
Compensation as of Fiscal Year 2014.

vetoquinol sa (VETO) Key Developments

Vétoquinol Launches UPCARD, an Innovative Drug for Congestive Heart Failure in Dogs

Vétoquinol continued the deployment of its reference products with the European launch of UPCARD, an innovative drug designed to treat congestive heart failure in dogs. With the launch of UPCARD in 2015, Vétoquinol brings to the market an innovative solution in the field of cardiology. UPCARD is the torasemide-based diuretic registered for veterinary use and forms a valuable addition to Vétoquinol's existing animal cardiology range. The efficacy of UPCARD treatment is rapidly visible: the once-a-day only administration makes it easier for pet owners to comply with the prescription. UPCARD improves the animal’s quality of life and its life expectancy.

Vétoquinol SA Announces Earnings Results for the Six Months of 2015

Vétoquinol SA announced earnings results for the six months of 2015. For the period, the company reported sales of EUR 167.2 million against EUR 149.4 million a year ago. EBIT was EUR 16.1 million against EUR 15.0 million a year ago, up 7.5% year-on-year reflecting the growing proportion of reference products in the sales mix and strict control over expenses and staff costs; first half of 2015 EBIT takes into account the amortization of Bioniche group identifiable assets, an amortization not yet started in first half of 2014. EBITDA was EUR 22.8 million against EUR 20.4 million a year ago. Net financial income came in at EUR 1.9 million primarily due to market volatility and more specifically a rise in the US dollar against the Euro. Group net income leapt 19.8% to EUR 12.4 million, up from EUR 10.4 million in first half of 2014.

Vétoquinol SA Reports Sales Results for the First Quarter of 2015

Vétoquinol SA reported sales results for the first quarter of 2015. For the quarter, the company reported sales of €81.3 million (after currency gains of €4.5 million), up by 11.0% to €73.2 million a year ago. At constant exchange rates, first quarter 2015 sales amounted to €76.7 million, a +4.8% increase from €73.2 million in first quarter of 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VETO:FP €40.75 EUR +0.62

VETO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Merck & Co Inc $50.14 USD 0.00
Sanofi €88.10 EUR +3.12
Virbac SA €161.35 EUR +4.85
Zoetis Inc $43.02 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation VETO Industry Range
Price/Earnings 17.1x
Price/Sales 1.4x
Price/Book 1.7x
Price/Cash Flow 11.4x
TEV/Sales 1.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VETOQUINOL SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at